• buy adobe acrobat 6 pro buy adobe lightroom student discount adobe acrobat 7 standard buy microsoft office 2010 activation key student discount rosetta stone spanish buy microsoft office for apple best price microsoft office 2007 professional buying adobe creative suite 5 design premium buy money 2008 deluxe cheap office outlook price of microsoft office 2013 in malaysia buy 3ds max 2009 singapore price of autodesk inventor publisher cheap adobe indesign cs2 price of archicad software
  • cheap microsoft office 2007 for students buy visio 2007 archicad pricing buy photoshop buy photoshop 5.5 cost of indesign buy 2007 outlook best buy autocad 2010 buy cheap mac os x leopard 10.5 cheap coreldraw graphics suite x4 buy office home and student 2007 product key outlook 2010 price buy filemaker pro 8.5 best price adobe photoshop elements 4 buy autodesk inventor 2011

    Tag Archive | "erbitux"

    Experimental EGFR inhibitor added nothing but rash

    Wednesday, March 19, 2014

    0 Comments

    Source: www.oncologypractice.com Author: Neil Osterweil, Oncology Report Digital Network The addition of the experimental targeted agent zalutumumab to primary curative chemoradiation for head and neck cancers did not improve locoregional control, disease-specific survival, or overall survival at 3 years of follow-up. The only thing that zalutumumab added to therapy was a skin rash in the […]

    Continue reading...

    Erbitux add-on falls short in esophageal cancer

    Monday, January 28, 2013

    0 Comments

    Source: www.medpagetoday.com Author: Charles Bankhead, Staff Writer, MedPage Today The addition of a targeted agent to definitive chemoradiation failed to improve survival in an unselected population with esophageal cancer, a randomized trial showed. In fact, patients who received cetuximab (Erbitux) with chemoradiation had significantly worse overall survival (OS) reflected in a 50% increase in the […]

    Continue reading...

    Scientists find new way to boost cancer drugs

    Monday, January 21, 2013

    0 Comments

    Source: www.drbicuspid.com Author: DrBicuspid Staff Shutting down a specific pathway in cancer cells appears to improve the ability of common drugs to wipe those cells out, according to new research from scientists at Fox Chase Cancer Center (Cancer Discovery, January 2013, Vol. 3:1, pp. 96-111). The new approach appears to enhance the tumor-killing ability of […]

    Continue reading...

    Germany’s Merck halts supply of cancer drug to Greek hospitals

    Monday, November 5, 2012

    0 Comments

    Source: Reuters.com Date: November 3, 2012 German pharmaceuticals firm Merck KGaA is no longer delivering cancer drug Erbitux to Greek hospitals, a spokesman said on Saturday, the latest sign of how an economic and budget crisis is hurting frontline public services. Drugmakers raised concerns with EU leaders earlier this year over supplies to the euro zone’s crisis-hit […]

    Continue reading...

    Facing the facts: HPV-associated head and neck cancers get a second look

    Tuesday, July 3, 2012

    0 Comments

    Source: www.curetoday.com Author: Charlotte Huff Kevin Pruyne knew he didn’t fit the stereotype of a hard drinker or heavy smoker who one day develops an oral cancer. The 52-year-old mechanic had been working a three-week stint in a remote section of northern Alaska, repairing trucks on an oil field, when he noticed a hard lump beneath […]

    Continue reading...

    Third Head and Neck Indication for Erbitux

    Thursday, January 5, 2012

    0 Comments

    Source: The ASCO Post, January 1, 2012, Volume 3, Issue 1, Matthew Stenger   In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.Cetuximab (Erbitux) was recently approved by the FDA for use in combination with platinum-based therapy […]

    Continue reading...

    FDA Approves Cetuximab for Late-Stage Head and Neck Cancer

    Wednesday, November 9, 2011

    0 Comments

    Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with […]

    Continue reading...

    US FDA approval for expanded use of Erbitux

    Wednesday, November 9, 2011

    0 Comments

    Source: www.pharmabiz.com Author: staff The US Food and Drug Administration (FDA) has approved Erbitux (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). The approval, which is based on data from the landmark EXTREME (ErbituX in first-line […]

    Continue reading...

    FDA Approves Cetuximab for Metastatic Head and Neck Cancer

    Tuesday, November 8, 2011

    0 Comments

    Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and neck cancer. Data show that when combined with cisplatin-based chemotherapy, cetuximab improved overall survival, compared with chemotherapy alone. According to the researchers, this is […]

    Continue reading...

    Cancer drug resistance strategy uncovered

    Friday, September 9, 2011

    0 Comments

    Source: Cancer Research UK Author: Staff   Friday 9 September 2011- US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying […]

    Continue reading...